Beursonline.nl

[verwijderd] 29 november 2019 07:26

0

Goedemorgen iedereen, hier een artikel 22 minuten geleden geplaatst:

Celyad Announces Board of Directors Evolution with New Appointment

Dr. Christian Homsy steps down from the Celyad Board of Directors as current CEO Filippo Petti is nominated into the role
MONT-SAINT-GUIBERT, Belgium, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that Filippo Petti, CEO of Celyad, is joining the Celyad Board of Directors and succeeds Celyad co-founder and former CEO Christian Homsy, M.D. who has resigned from Celyad’s Board of Directors.

“I am proud of and thankful to the Celyad team for what they have accomplished over the years. I wish them and Filippo the best for the future,” said Dr. Homsy.

“I’d like to thank Christian for his guidance and support during the past few months as I’ve transitioned into the role of CEO,” said Filippo Petti, CEO of Celyad. “I am honored to accept this appointment to Celyad’s Board of Directors and I look forward to continuing to work closely with the Board to execute on the Company’s strategic vision.”

Michel Lussier, Chairman of Celyad, noted, “We thank Christian for all his leadership and dedication since his co-founding of Celyad. His impact on the Company has been tremendous. Though he is leaving our Board, we know he will remain intensely interested in the Company’s future progress towards becoming a leader in the field of CAR-T cell therapy. We are also very pleased to welcome Filippo on the Board.”

About Celyad

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based product candidates and utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. The company’s lead clinical candidate, CYAD-01, an autologous NKG2D-based CAR-T therapy, is currently being evaluated in several Phase 1 clinical trials to assess safety and clinical activity for the treatment of hematological malignancies, such as acute myeloid leukemia, and solid cancers, such as metastatic colorectal cancer. Celyad is also developing CYAD-101, an investigational, non-gene edited, allogeneic (donor derived) NKG2D-based CAR-T therapy, which is currently being evaluated in a Phase 1 trial for the treatment of patients with metastatic colorectal cancer. Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the Nasdaq Global Market, all under the ticker symbol CYAD. Celyad has received funding from the Walloon Region (Belgium) to support the advancement of the Company’s autologous and allogeneic CAR-T cell therapy programs.

For more information, please contact:

Celyad
Filippo Petti, Chief Executive Officer – investors@celyad.com
Alexandrine Hazard, Communications Associate – T: +32(0) 10 39 41 58 – communications@celyad.com
For Europe: Ulysse Communication
Bruno Arabian – T.: +33 (0)6 87 88 47 26 – barabian@ulysse-communication.com
U.S.: LifeSci Advisors
Investor Relations: Daniel Ferry – T.: +1 (617) 535 7746 – daniel@lifesciadvisors.com
Public Relations: Sara Zelkovic – T.: +1 (646) 876 4933 – sara@lifescipublicrelations.com

Forward-looking statements

This release may contain forward-looking statements, including statements regarding: the safety and clinical activity of CYAD-01, CYAD-101 and CYAD-02; statements regarding the ongoing and planned clinical development of CYAD-01, CYAD-101 and CYAD-02, including the timing of trials, enrolment, data readouts and presentations; the clinical and commercial potential of CYAD-01, CYAD-101 and CYAD-02; and our mAb manufacturing processes. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual results, financial condition and liquidity, performance or achievements of Celyad, or industry results, to differ materially from those expressed or implied by such forward-looking statements. In particular it should be noted that the data summarized above are preliminary in nature. There is limited data concerning safety and clinical activity following treatment with the CYAD-01, CYAD-101 and CYAD-02 drug product candidates. Our therapeutic candidates manufactured using our OptimAb process have not yet been evaluated in clinical trials. Prior clinical and preclinical results may not be repeated or observed in ongoing or future clinical studies involving the CYAD-01 and CYAD-101 drug product candidates. These forward-looking statements are further qualified by important factors and risks, which could cause actual results to differ materially from those in the forward-looking statements, including statements about: the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our ability to advance drug product candidates into, and successfully complete, clinical trials; our ability to successfully manufacture drug product for our clinical trials, including with our OptimAb manufacturing process and with respect to manufacturing drug product with the desired number of T cells under our clinical trial protocols; our reliance on the success of our drug product candidates, including our dependence on the regulatory approval of CYAD-01, CYAD-101 and CYAD-02 in the United States and Europe and subsequent commercial success of CYAD-01, CYAD-101 and CYAD-02, both of which may never occur; the timing or likelihood of regulatory filings and approvals; our ability to develop sales and marketing capabilities; the commercialization of our drug product candidates, if approved; the pricing and reimbursement of our drug product candidates, if approved; the implementation of our business model, strategic plans for our business, drug product candidates and technology; the scope of protection we are able to establish and maintain for intellectual property rights covering our drug product candidates and technology; our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties; cost associated with enforcing or defending intellectual property infringement, misappropriation or violation; product liability; and other claims; regulatory development in the United States, the European Union, and other jurisdictions; estimates of our expenses, future revenues, capital requirements and our needs for additional financing; the potential benefits of strategic collaboration agreements and our ability to maintain and enter into strategic arrangements; our ability to maintain and establish collaborations or obtain additional grant funding; the rate and degree of market acceptance of our drug product candidates, if approved; our financial performance; developments relating to our competitors and our industry,

[verwijderd] 29 november 2019 07:26

0

including competing therapies and statements regarding future revenue, hiring plans, expenses, capital expenditures, capital requirements and share performance. A further list and description of these risks, uncertainties and other risks can be found in Celyad’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on April 5, 2019 and subsequent filings and reports by Celyad. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document and Celyad’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

Bron: www.globenewswire.com/news-release/20...

[verwijderd] 29 november 2019 07:44

0

Goedeorgen henkie, hier de vertaling nederlands,

Celyad kondigt Raad van Bestuur Evolutie met nieuwe benoeming aan

29 november 2019 01:00 ET | Bron: Celyad SA
Dr. Christian Homsy treedt terug als lid van de raad van bestuur van Celyad, terwijl de huidige CEO Filippo Petti wordt genomineerd voor de rol
MONT-SAINT-GUIBERT, België, 29 november 2019 (GLOBE NEWSWIRE) - Celyad (Euronext Brussel en Parijs en Nasdaq: CYAD), een biofarmaceutisch bedrijf in de klinische fase dat zich vandaag toelegt op de ontwikkeling van CAR-T-celtherapieën kondigde aan dat Filippo Petti, CEO van Celyad, toetreedt tot de Raad van Bestuur van Celyad en de opvolger is van Celyad mede-oprichter en voormalig CEO Christian Homsy, MD die ontslag heeft genomen uit de Raad van Bestuur van Celyad.

“Ik ben trots op en dankbaar voor het Celyad-team voor wat ze door de jaren heen hebben bereikt. Ik wens hen en Filippo het beste voor de toekomst, ' zei Dr. Homsy.

"Ik wil Christian graag bedanken voor zijn begeleiding en ondersteuning tijdens de afgelopen maanden, toen ik ben overgestapt naar de rol van CEO," zei Filippo Petti, CEO van Celyad. "Ik ben vereerd deze benoeming in de Raad van Bestuur van Celyad te aanvaarden en ik kijk ernaar uit om nauw samen te blijven werken met de Raad om de strategische visie van de onderneming uit te voeren."

Michel Lussier, voorzitter van Celyad, merkte op: “We danken Christian voor al zijn leiderschap en toewijding sinds zijn mede-oprichting van Celyad. Zijn impact op het bedrijf is enorm geweest. Hoewel hij onze raad verlaat, weten we dat hij intens geïnteresseerd zal blijven in de toekomstige vooruitgang van het bedrijf om een ??leider te worden op het gebied van CAR-T-celtherapie. We zijn ook erg verheugd om Filippo in het bestuur te verwelkomen. ”

[verwijderd] 29 november 2019 07:48

0

Ik had liever een bericht gekregen over een grote verandering in hun resultaten dan over zoiets, maar bon,

twopence 29 november 2019 08:10

0

Verandering kan positief ontwikkelingen teweeg brengen.
Afwachten wat dit gaat brengen.

Guus_Geluk 29 november 2019 08:50

0

quote:
Kaviaar schreef op 28 november 2019 19:47:
Ik was in het verleden te laat met ArgenX. Bij Celyad blijf ik zitten en hoop ook een forse stijging mee te maken.
Celyad heeft goede resultaten behaald, maar de koers is daar nog lang niet naar.
Als Celyad het voor elkaar bokst, dan kunnen veel patiënten geholpen worden.

Precies. Galapagos stond wat jaren terug ook op 10 euro. Het kan een hele mooie rit worden met Celyad.

[verwijderd] 29 november 2019 08:50

0

Vandaag 12eu aantikken

[verwijderd] 29 november 2019 08:54

0

quote:
Kiadis-Kenner schreef op 29 november 2019 08:50:
Vandaag 12eu aantikken

Op basis waarvan?

[verwijderd] 29 november 2019 09:06

0

Theo opening 10,6

Guus_Geluk 29 november 2019 09:11

0

quote:
Twin schreef op 29 november 2019 07:48:
Ik had liever een bericht gekregen over een grote verandering in hun resultaten dan over zoiets, maar bon,

Er wordt wel vertrouwen uitgesproken naar de huidige CEO.

[verwijderd] 29 november 2019 09:25

0

quote:
FluitendeVogels schreef op 29 november 2019 08:54:
[...]

Op basis waarvan?

Basis van indicatoren.

nog een euro

Guus_Geluk 29 november 2019 09:39

0

quote:
Kiadis-Kenner schreef op 29 november 2019 09:25:
[...]

Basis van indicatoren.

Welke dan? ;-)

[verwijderd] 29 november 2019 09:59

0

quote:
Guus_Geluk schreef op 29 november 2019 09:39:
[...]
Welke dan? ;-)

Maakt mij niet uit. Close rond de 11 zou technisch goed zijn.

Guus_Geluk 29 november 2019 10:03

0

quote:
g62333 schreef op 29 november 2019 09:59:
[...]

Maakt mij niet uit. Close rond de 11 zou technisch goed zijn.

11 euro, waar praten we eigenlijk over.. dit aandeel hoort véél hoger te staan. Profiteer van deze lage koers nu het nog kan.

[verwijderd] 29 november 2019 10:06

0

12, mark my word.

Guus_Geluk 29 november 2019 10:09

0

11.34 heeft vandaag in ieder geval al op de borden gestaan.

Noob nr1 29 november 2019 10:17

0

Nice spike...

[verwijderd] 29 november 2019 10:17

0

quote:
Guus_Geluk schreef op 29 november 2019 10:03:
[...]
11 euro, waar praten we eigenlijk over.. dit aandeel hoort véél hoger te staan. Profiteer van deze lage koers nu het nog kan.

Dat t hoger moet staan daar is geen discussie over. Ik houd ze gewoon bij voor lange termijn...

Guus_Geluk 29 november 2019 10:23

0

quote:
Noob nr1 schreef op 29 november 2019 10:17:
Nice spike...

Het lijkt geen spike te zijn, de hele laat wordt opgekocht.

[verwijderd] 29 november 2019 10:32

0

quote:
Guus_Geluk schreef op 29 november 2019 10:23:
[...]

Het lijkt geen spike te zijn, de hele laat wordt opgekocht.

Kan je mij jouw link eens geven met bied/laat?

Vertraagd	14 feb 2025 17:35
Koers	0,411
Verschil	-0,014 (-3,30%)
Hoog	0,425
Laag	0,410
Volume	4.898
Volume gemiddeld	42.214
Volume gisteren	5.463

Celyad « Terug naar discussie overzicht

CELYAD 2019 Nieuws

Meedoen aan de discussie?

Direct naar Forum

Detail

Celyad nieuws meer